Physician

Michael Zlupko

According to 2025 Medicare claims, Michael Zlupko (NPI: 1114121647) practices critical care (intensivists) in the Altoona, PA market, with the plurality of this provider's patient population coming from Blair, PA. This provider's primary affiliated billing organization is ALTOONA LUNG SPECIALISTS (NPI: 1457394835; TIN: 251384796) and primary practice location at 16602-4165. Zlupko is affiliated with the AdvantagePoint Health Alliance - Laurel Highlands, LLC (ACO ID: A4657), participating under the MSSP model.

Zlupko's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 522 traditional Medicare patients, billed 3,006 HCPCS/CPT codes, and received $180,610 in Medicare payments. The top billing code was 99233 (Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes). Part D data shows 3,251 prescription claims across 439 beneficiaries totaling $2,064,237 in drug costs, led by Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter). DME data shows 630 claims. Open Payments data shows 155 records totaling $116,840. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $101,599 to $180,610. Similarly, Part D prescription costs have risen steadily, from $347,635 to $2,064,237. In contrast, DME billing represents a smaller volume and moved from a lower plateau to a higher plateau, from $15,833 to $37,408.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	299	2,167	$101,599
2016	325	2,089	$100,605
2017	392	3,590	$132,446
2018	395	2,836	$125,070
2019	382	2,273	$119,173
2020	361	2,169	$99,425
2021	356	2,940	$117,809
2022	376	2,345	$102,137
2023	517	3,259	$168,129
2024	522	3,006	$180,610

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	146	796	$347,635
2016	208	1,141	$368,005
2017	274	1,891	$933,539
2018	321	2,325	$1,076,650
2019	370	2,891	$1,385,419
2020	401	3,232	$1,664,664
2021	403	3,239	$2,202,744
2022	393	3,129	$2,458,760
2023	434	3,238	$2,406,925
2024	439	3,251	$2,064,237

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	12	270	$29,251
2016	17	299	$26,472
2017	23	334	$20,120
2018	77	569	$40,963
2019	74	725	$60,894
2020	62	725	$74,763
2021	71	637	$52,162
2022	80	762	$44,028
2023	74	824	$59,542
2024	57	630	$32,549

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	160	351	$89
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	235	434	$87
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	234	1,070	$59
94729	Test to examine how well the lungs exchange gases	102	146	$40
94010	Test to measure expiratory airflow and volume	167	282	$19

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	796	28,800	$593,067
Prolastin C	Alpha-1-Proteinase Inhibitor	26	714	$280,893
Ofev	Nintedanib Esylate	20	600	$260,663
Nucala	Mepolizumab	35	1,204	$155,416
Breo Ellipta	Fluticasone/Vilanterol	223	9,600	$122,006

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	31	217	$17,842
J7606	Formoterol fumarate, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 20 micrograms	N	N/R	53	$6,778
J7626	Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg	N	N/R	32	$1,833
Q0513	Pharmacy dispensing fee for inhalation drug(s); per 30 days	N	13	67	$1,700
E1392	Portable oxygen concentrator, rental	Y	N/R	52	$1,609

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	138	$49,920	GlaxoSmithKline, LLC.
Research Payments	Reported research-related payment or transfer-of-value amount.	17	$66,920	GlaxoSmithKline, LLC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Michael Zlupko?

Tedicare shows public-source Medicare data for Michael Zlupko (NPI 1114121647), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Michael Zlupko have ACO affiliation data?

Michael Zlupko is shown with ACO affiliation data for AdvantagePoint Health Alliance - Laurel Highlands, LLC (MSSP, ACO ID A4657).

What billing organization is linked to Michael Zlupko?

Michael Zlupko is linked to ALTOONA LUNG SPECIALISTS (billing NPI 1457394835) in the available physician profile data.

Does Michael Zlupko have Open Payments data?

Michael Zlupko has 155 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.